David Altshuler sold $1.6M of VRTX
EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA. 3,231 shares at an average of $490.00, traded Mar 3, 2025, filed Mar 5, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.6M at market
- 0Share of holdings soldSold 9.8% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-25-000139, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -3,231 | $490.00 | $1.6M | 29,743 | Mar 5, 2025 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $22k 52 shares | -0% | |
| 15Weak | VERTEX PHARMACEUTICALS INC / MA | Sangeeta N. Bhatia director | $202k 400 shares | -8% | |
| 33Weak | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $1.6M 3,231 shares | -12% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $1.6M 3,231 shares | -11% | |
| 30Weak | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $611k 1,272 shares | -4% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $1.3M 2,650 shares | -12% | |
| 26Weak | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $408k 848 shares | -2% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $425k 884 shares | -9% | |
| 33Weak | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $850k 1,767 shares | -7% | |
| 28Weak | VERTEX PHARMACEUTICALS INC / MA | David Altshuler EVP, Chief Scientific Officer | $533k 1,111 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.